All In Biotech

Drug Trial Radar · NCT03502785

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

35

Actual

Start

Jul 24, 2018

Primary completion

May 9, 2025

Study completion May 9, 2025

Sponsor

Lead sponsor
Inovio PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). The trial population was divided into two cohorts: Cohort A: participants with locally advanced unresectable or metastatic/recurrent UCa, who had confirmed disease progression during or following treatment with anti-programmed death receptor-1/programmed death receptor ligand-1 (anti-PD-1/PD-L1) therapy; Cohort B: participants with locally advanced unresectable or metastatic/recurrent UCa, who were treatment naïve and ineligible for cisplatin-based chemotherapy. A safety run-in was performed using a modified rolling six design, enrolling up to 6 participants (safety analysis participants) from Cohort A.

Conditions

  • Urothelial Carcinoma

Interventions

  • INO-5401Biological

    INO-5401: A mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen. IM injection

  • INO-9012Biological

    INO-9012: A synthetic plasmid that expresses human interleukin-12 (IL-12). IM injection.

  • AtezolizumabDrug

    IV-Infusion.

  • CELLECTRA® 2000Device

    IM injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) TreatmentTime frame: Up to approximately 71 months
  2. Number of Participants With Clinically Significant Changes in Hematological ParametersTime frame: Up to approximately 71 months
  3. Number of Participants With Clinically Significant Changes in Serum Chemistry ParametersTime frame: Up to approximately 71 months
  4. Number of Participants With Clinically Significant Changes in Urinalysis ParametersTime frame: At baseline, Weeks 3, 6, 9, then every 6 weeks thereafter, up to 71 months
  5. Antigen-Specific Immune ResponseTime frame: Up to approximately 71 months
  6. Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Review in Cohort ATime frame: From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Cancer Center

    Phoenix, Arizona

  • H. Lee Moffitt Cancer Center & Research Institute, Inc.

    Tampa, Florida

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • New York University Langone Medical Center - Perlmutter Cancer Center

    New York, New York

  • Columbia University, Herbert Irving Comprehensive Cancer Center

    New York, New York

  • University of North Carolina School of Medicine

    Chapel Hill, North Carolina

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Greenville Memorial Hospital

    Greenville, South Carolina

  • Inova Melanoma and Skin Cancer Center

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.